Kornimate/medical-research-clean huggingface dataset:
prognostic biomarkers of pancreatic cancer based on proteomics techniques

Conditions: Patients

Summary: in this study, we will use high-throughput proteomics techniques to search for biomarkers of post-operative prognosis of pancreatic cancer in samples of patients who have been diagnosed with pancreatic cancer through bioinformatics analysis.

this study plan from the affiliated hospital of qingdao university collected 20 cases of patients with pancreatic cancer pathological tissue samples and clinical data, including clinical diagnostic information, laboratory tests, imaging examination results and other information data), through high-throughput proteomic technology in pancreatic cancer pathological finding biomarkers, the bioinformatics analysis to explore the prognosis biomarkers.

Eligibility criteria:
inclusion criteria: * patients of chinese nationality, age and gender are not limited. * pathologically confirmed pancreatic cancer patients. * pathological specimens were archived tumor tissue samples after a diagnosis of pancreatic cancer. * clinical diagnostic information was complete three months before sampling. exclusion criteria: * patients with a second primary tumor.
comparison between levobupivacaine and levobupivacaine with dexmedetomidine in ultrasound guided pectoral nerve block

Conditions: Breast Cancer; Mastectomy, Modified Radical

Summary: a double blind prospective randomized controlled trial in which the effect of single shot levobupivacaine 0,25% will be compared with the effect of levobupivacaine 0.25% in association with dexmedetomidine when performing an ultrasound guided modified pectoral nerve block , in patients undergoing a mastectomy with axillar procedure. the difference in effect will be evaluated by monitoring the postoperative morphine consumption in both groups . the hypothesis is that there is a significant decrease in morphine consumption during the first 24h postoperatively due to association of dexmedetomidine to the local anesthetic compared to the local anesthetic alone when performing a ultrasound guided modified pectoral nerve block. the morphine consumption will be the primary outcome parameter.

women (18+, american society of anesthesiologists 1,2,3) undergoing a mastectomy with axillar procedure will be randomised and receive a ultrasound guided modified pectoral nerve block, if participants meet in- and exclusion criteria and provide written informed consent. using a two needle approach, ten milliliters of local anesthetic is injected under ultrasound guidance between the major and minor pectoral muscle and twenty milliliters between the minor pectoral and the serratus anterior muscle, on the side to be operated. participants receive intravenous patient controlled analgesia with morphine and dehydrobenzperidol (1mg/ml morphine, 50µg dehydrobenzperidol/ml). furthermore every participant in the trial will receive ketorolac 0.5mg/kg three times a day and paracetamol four times 1g per day. when the analgesia using the intravenous patient controlled analgesia regime isn't sufficient, the anesthesiologist will titrate with morphine until pain free using a protocol (a bolus of 2mg morphine iv every ten minutes until pain free).

Eligibility criteria:
inclusion criteria: * women, * 18years and older * american society of anesthesiologists 1, 2,3, * planned for radical mastectomy. exclusion criteria: * neurological problems (central and peripheral) * bilateral mastectomy * body mass index \> 33, * absolute contra-indication for ketorolac. * allergy/over-sensitiveness to levobupivacaine or local anesthetics of the same class * allergy/over-sensitiveness to dexmedetomidine or other alpha2 agonists (clonidine) * anatomic variations of the breast, pectoral region or axilla, noticed at clinical examination, including a pacemaker, implantable cardioverter defibrillator, port-a-cath or other implantable device on the side that needs surgery. * participation in an other clinical trial within a period of four weeks before the beginning of this trial. * coagulopathy * infection or abcess in the region where the block will be placed. * pregnancy

Keywords: pectoral block ultrasound mastectomy levobupivacaine dexmedetomidine
immuno-inflammation in the acute phase of an ischaemic cerebral accident managed by decompressive hemicraniectomy: a case-control study

Conditions: Ischemic Cerebrovascular Accident

Summary: the objective of the neutrosurgery study is to describe the local and locoregional immuno-inflammatory activity in patients suffering from malignant sylvian ischaemic cerebral accident and treated with decompressive hemicraniectomy compared to a control population of patients to be operated on in neurosurgery for another neurosurgical pathology.


Eligibility criteria:
inclusion criteria patients: * collegial indication given by a neurologist, a neuroreanimator and a neurosurgeon for hd in the context of a malignant sylvian aic. inclusion criteria control: - for neurosurgical operations in which cranial, meningeal, vascular (branch of the middle meningeal artery) or cerebral bone tissue is not preserved during the surgical approach. non-inclusion criteria patients: * hd carried out in a context of acute cerebral haemorrhage * pre-existing neurological disability: modified rankin score \> 2 * patient benefiting from a legal protection measure non-inclusion criteria controls: * patient to be operated on for an acute vascular condition: meningeal haemorrhage, subdural or extradural haemorrhage, intra parenchymal haemorrhage. * patient operated on for an osteomeningeal pathology present at the approach site. * patient operated on for an infectious cranial or neuro-meningeal pathology. * patient to be operated on as a result of an intracranial traumatic condition
epididymis protein 4 and pulmonary function with quality improvement protocol among cystic fibrosis patients

Conditions: Cystic Fibrosis (CF)

Summary: to implement a quality improvement plan aimed at achieving a 5% increase in the forced expiratory volume in 1st second (fev1) (% predicted value) in cystic fibrosis (cf) patients with impaired pulmonary function parameters over 12 months. additionally, the plan aims to measure serum human epididymis protein 4 (he4) levels in the studied subjects before and after pulmonary function improvement.

this study will be conducted on 35 children diagnosed with cystic fibrosis, aged between 6 and 18 years. patients will be selected during their follow-up visits to the pediatric chest clinic at ain shams university hospital. inclusion criteria: a. pediatric cystic fibrosis patients diagnosed based on the consensus guidelines from the cystic fibrosis foundation, with a positive sweat chloride test (≥60 milliequivalent/l) and/or the presence of two cystic fibrosis disease-causing gene mutations. b. age ≥6 years. c. forced expiratory volume in 1st second (fev₁) ≤80%. exclusion criteria: a. patients unable to perform spirometry. all subjects in the study will undergo an interventional quality improvement plan. a specialized clinic for cf patients will be established based on the quality improvement (qi) plan, where patients will be followed up every three months by a specialized multidisciplinary team, including a pediatric pulmonologist, pediatric nutrition consultant, pediatric gastroenterologist, chest physiotherapist, and pediatric endocrinologist. each specialized clinic will develop and implement standardized cystic fibrosis care algorithms and individualized treatment plans for each patient. these algorithms and plans will be continuously adjusted based on challenges encountered during follow-up to address barriers and deficiencies that may contribute to poor outcomes. areas needing improvement will be identified, and appropriate resources and strategies will be proposed. this will include the development of fishbone diagrams, flowcharts, plan-do-study-act (pdsa) cycles, pdsa ramps, and other quality improvement tools to address specific deficiencies. additionally, training and engaging the team in quality improvement methodologies will be conducted. patients will undergo pulmonary function tests at baseline, followed by assessments at six months and one year during the study.

Eligibility criteria:
inclusion criteria: * pediatric cf patients diagnosed based on the consensus guidelines from the cystic fibrosis foundation, with a positive sweat chloride test (≥60 milliequivalent/l) and/or the presence of two cf disease-causing gene mutations. * age ≥6 years. * forced expiratory volume in 1 second (fev₁) ≤80%. exclusion criteria: ●patients are unable to perform spirometry.

Keywords: quality improvement (qi)
motivation, syringe exchange, and covid-19

Conditions: COVID-19 Pandemic

Summary: people who inject drugs (pwids) are highly vulnerable to sars-cov-2 infection and to the disease caused by sars-cov-2, coronavirus disease 2019 (covid-19), however, rates of sars-cov-2 testing and vaccination uptake -vital to mitigating the spread of covid-19 and achieving herd immunity - are lower among pwids compared to the general population. building on our phase i rapid acceleration of diagnostics project, which found that contingency management (cm) increased testing utilization among pwids, the proposed project evaluates the comparative effectiveness of cm versus cm plus a brief motivational enhancement intervention on sars-cov-2 testing and vaccination uptake among pwids. this project has the potential to reduce covid-19 health disparities among pwids and to decrease population level covid-19 morbidity and mortality.

this study uses contingency management, specifically $10 financial incentives for participation in sars-cov-2 testing and $10 for participating in covid-19 vaccination. it also uses a motivational enhancement intervention which is a brief conversation with clients to improve intrinsic motivation for testing and vaccination. thus, the clinical trials portion of this study is a randomized control trial (n = 349) in which 177 participants will be assigned to contingency management plus the connect2test intervention and 172 will be assigned to the contingency management alone (i.e. services as usual). there will be a per site quota to ensure there are relatively equivalent numbers of participants per site to avoid site-specific biases. the data collection software (e.g., qualtrics, powerbi) will randomly assign individuals to condition in real time, after a participant consents to participate in the study.

Eligibility criteria:
inclusion criteria: * 18 and older, understand english exclusion criteria: * none
investigation of a polyphenol-rich preparation as support for oncology patients undergoing gastrointestinal tumor resection

Conditions: Immunomodulation

Summary: the aim of the study is to demonstrate, under clinical conditions, the effectiveness of the standard product 'nutridrink' enriched with a mixture of plant extracts rich in polyphenolic compounds in the aspect of supporting the recovery of oncology patients undergoing surgical resection of tumours.

oncology patients undergoing the procedure are exposed to various postoperative complications. nutridrink with a mixture of extracts with anti-inflammatory and antioxidative properties aims to provide the patient with essential nutrients and bioactive substances that can reduce the inflammatory state, protect cells from oxidative damage, and decrease the risk of complications while supporting tissue healing processes after the surgical procedure. the study group are oncology patients undergoing surgical resection of gastrointestinal tumour. during the study, the effects of the mixture on levels of oxidative stress and inflammation markers will be assessed, as well as the subjective evaluation of patients' quality of life and well-being after surgical surgical tumor resection.

Eligibility criteria:
inclusion criteria: * women and men, 18-80 years old * patients diagnosed with resectable gastrointestinal tract cancer undergo the resection procedure no later than one month after being enrolled in the study * signed informed consent exclusion criteria: * intake of supplements containing plant extracts, polyphenols or anthocyanins * participation in another clinical trial * inability to consume the investigational product in liquid form as medication/placebo * women who are pregnant, planning to become pregnant during the study or breastfeeding * autoimmune disease, severe liver dysfunction, inflammatory bowel disease, tuberculosis, multiple sclerosis, aids, rheumatoid arthritis, organ transplantation * hypersensitivity/allergy to any of the ingredient

Keywords: chokeberry nutridrink immunomodulation tumor resection
pilot test of patient decision aid for opioid use disorder

Conditions: Opioid Use Disorder

Summary: the aims of the current study phase (r21) are: aim 1. develop a patient decision aid (ptda-mat) by incorporating best available scientific evidence on mat as well as feedback from patients and clinical providers related to clinical priorities, perceived utility, and acceptability; aim 2. conduct pilot testing of the ptda-mat in an iterative process guided by an expert panel and involving key stakeholders (e.g., patients, physicians, policymakers) and field-testing.

in response to rfa-da-18-005 (expanding medication assisted treatment for opioid use disorders in the context of the samhsa opioid str grants, r21/r33), this project will develop and test a patient decision support tool called patient decision aid for medication-assisted treatment (ptda-mat) for use in the ca h\&ss. the ptda-mat is designed to (1) improve patient knowledge and involvement and to subsequently improve treatment adherence and outcomes and (2) to support clinicians in informing and communicating with their patients with oud along a continuum of care. the project will conduct 1 year of r21 to develop and pilot-test the ptda-mat to facilitate shared decision making in ca h\&ss, followed by 3 years of r33 to assess the effectiveness of the ptda-mat in a randomized controlled trial. the aims of the current study phase (r21) are: aim 1. develop a patient decision aid (ptda-mat) by incorporating best available scientific evidence on mat as well as feedback from patients and clinical providers related to clinical priorities, perceived utility, and acceptability; aim 2. conduct pilot testing of the ptda-mat in an iterative process guided by an expert panel and involving key stakeholders (e.g., patients, physicians, policymakers) and field-testing.

Eligibility criteria:
inclusion criteria: * opioid use disorder diagnosis and agreement to follow study procedures (including permission to share medical records and other administrative records) exclusion criteria: * significant or unstable medical or psychiatric illness that may interfere with study participation

Keywords: opioid use disorder (oud) medication assisted therapy (mat) patient decision aid
neuroinflammation in asymptomatic carotid artery disease - imaging substudy

Conditions: Critical Asymptomatic Carotid Artery Disease; Non-Critical Asymptomatic Carotid Artery Disease

Summary: this clinical imaging substudy will use the small molecule translocator protein (tspo) ligand, fludeoxyglucose(18f)-labeled dpa-714, to compare neuroinflammation in individuals with high or low grade asymptomatic carotid artery stenosis (acad) who are participating in the separate neuroinflammation in asymptomatic carotid artery disease study lead by dr. ron lazar (irb-300007806). the positron emission tomography (pet) tracer \[18f\]dpa-714 binds to the 18 kda translocator protein (tspo, also known as the peripheral benzodiazepine receptor) in the mitochondria of activated microglia/macrophages and provides a non-invasive measure of neuroinflammation.


Eligibility criteria:
inclusion criteria: cohort 1 - critical asymptomatic carotid stenosis group inclusion criteria: 1. critical stenosis group: diagnosis of asymptomatic carotid artery disease (acad) with \>70% stenosis or peak systolic velocity on dus ≥ 230 cm/s plus cta or mra confirmation. 2. participation in university of alabama at birmingham (uab) irb protocol "neuroinflammation in asymptomatic carotid artery disease" (irb-300007806, pi lazar). 3. male or female age \>18 years 4. english speaking with at least 8th grade education 5. high affinity binder for tspo ligands based on genotyping for single nucleotide polymorphism (snp) rs6971 6. planned revascularization for acad in \>14 days from time of consent cohort 2 - non-critical asymptomatic carotid stenosis group inclusion criteria: 1. participation in uab irb protocol "neuroinflammation in asymptomatic carotid artery disease" (irb-300007806, pi lazar). 2. \<40% carotid stenosis 3. no planned revascularization 4. male or female age 18 or older 5. english speaking with at least 8th grade education 6. high affinity binder for tspo ligands based on genotyping snp rs6971 exclusion criteria: 1. contraindication to mri 2. pregnancy or lactation 3. previous revascularization for treatment of acad 4. prior stroke 5. severe anemia (blood hemoglobin ≤ 8 mg/dl) 6. previously obtained mri scan with evidence of clinically significant abnormality 7. history of traumatic head injury defined by loss of consciousness \>30 minutes or seizure at the time of the injury 8. major depression 9. known history of dementia 10. serious medical comorbidity that, based on the judgement of the principal investigator, may interfere with study participation 11. low or mixed-affinity binding for tspo ligands based on genotyping for snp rs6971.
measurements of sexual steroids' concentrations in prostatic tissue

Conditions: Bladder Cancer

Summary: in the investigators's previous work, measurements of intra-prostatic concentrations of sex steroids were determined on samples taken from the operating room using a punch. in order to study the in-vivo intra-prostatic concentrations of sex steroid, it is necessary to validate a measurement technique performed on samples obtained by a biopsy needle used in standard care for prostate biopsy punctures allowing the diagnosis and follow-up of prostate cancer. the aim of this project is to validate this measurement technique carried out on samples obtained by the biopsy needle and to define the optimal number of carrots obtained by biopsy offering dosage results comparable to the punch.


Eligibility criteria:
inclusion criteria: * patient aged ≥ 18 years * with a bladder cancer * should be operated by total cystoprostatectomy at foch hospital * affiliated to a health insurance scheme * having expressed the non-opposition for the participation to the study exclusion criteria: * patient receiving or has received a treatment by analog or antagonist of luteinizing hormone releasing hormone (lhrh), antiandrogens (steroidal or non-steroidal), 5 alpha-reductase inhibitor, docetaxel or cabazitaxel chemotherapy, abiraterone acetate, enzalutamide or corticosteroids * patient who does not understand french * patient deprived of liberty or under guardianship

Keywords: steroids' concentrations biopsy needle cystoprostatectomy
modified process hepatitis b vaccine in healthy neonates (v232-056)

Conditions: Hepatitis B; Hepatocellular Carcinoma

Summary: hepatitis b vaccine \[recombinant\] is a well-established vaccine which has been used extensively, worldwide since its initial licensure in 1986. hepatitis b vaccines: \[1\] induce protection against the morbidity and mortality of acute hepatitis b virus infection, \[2\] reduce the incidence of chronic infection in vaccinated populations, and \[3\] thereby, reduce the incidence of hepatocellular carcinoma. the purpose of the trial is to assess if the new manufacturing process of the hepatitis b vaccine \[recombinant\] vaccine shows the same level of hepatitis b antibody response or better as the currently licensed hepatitis b vaccine \[recombinant\] vaccine. this study will also confirm that the new process vaccine is as well tolerated as the current vaccine.


Eligibility criteria:
inclusion criteria: * healthy male and female full-term (37-42 weeks gestation) neonates (birth to 10 days of age) * born to mothers with documented negative test for hbsag within 9 months prior to delivery exclusion criteria: * infant born to mother with no prenatal care * known or suspected impairment of immunologic function * prior vaccination with any hepatitis b vaccine for infant or mother(within 6 months prior to the birth of infant.) * recent(\ /= 99.5 degrees f (\>/= 37.5 degrees c) axillary or \>/= 100.5 degrees f (\>/= 38.1 degrees c) rectal * any prior administration of hepatitis b immune globulin (hbig), serum immune globulin, or any other blood-derived product, or the receipt by the mother of either immunoglobulin or hbig within 6 months prior to birth of the infant * receipt of investigational vaccines by mother or infant within 3 months prior to first injection with study vaccine or if scheduled to be given to the infant during the study * known or suspected hypersensitivity to any component of study vaccine (e.g., aluminum, yeast) * any infant who cannot be adequately followed for study visits during the course of the clinical study * any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives
telehealth to reduce suicidality and improve hiv care engagement in tanzania

Conditions: Suicide; Suicidal Ideation; HIV Infections; Adherence, Medication; Treatment Adherence and Compliance; Stigma, Social; Disclosure; Quality of Life

Summary: the overall objectives of the proposed research are to develop a brief telehealth counseling intervention to provide support for people living with hiv and experiencing suicidal ideation, and to support hiv care engagement. the investigators hypothesize that a brief telehealth counseling intervention will be safe (participants in the clinical trial will not have increased risk of suicidal behavior), acceptable (high patient retention and satisfaction, high fidelity), and will demonstrate preliminary efficacy (reduced suicidal ideation, improved care engagement, improved mental well-being).

the objective of the proposed research is to assess the feasibility and acceptability of a 3-session, nurse-delivered telehealth intervention to reduce suicidality and improve hiv care engagement among adults living with hiv in the kilimanjaro region of tanzania. suicide is a leading cause of death among people living with hiv (plwh) worldwide and mental health disorders are key contributors to poor hiv care engagement, lower quality of life, higher transmission risk, and increased mortality among plwh. conversely, connecting plwh with targeted mental health support improves these critical health outcomes. telehealth counseling represents a cost-effective, innovative approach to mental health treatment in low-resource settings such as tanzania, with the potential to expediently extend services. the proposed study will include aim 1: identifying the desired characteristics of a telehealth intervention for suicidality and hiv care engagement in the tanzanian clinical context, aim 2: refining intervention content with support from a local study advisory board in tanzania, and aim 3: testing the telehealth model in a pilot randomized control trial. given emerging evidence for telehealth approaches to improve access to treatment and reduce health disparities, the intervention has great potential to support nimh strategic objectives to address mental health comorbidities and strengthen the hiv care continuum.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * attending hiv care at study clinic * screen positive for suicidal ideation * able to understand kiswahili or english * medically stable * capable of providing informed consent to participate exclusion criteria: * under 18 years old * unable to understand kiswahili or english * experiencing medical or psychiatric symptoms requiring immediate treatment * incapable of providing informed consent to participate